In the study, Leonid Metelitsa and colleague from Childrens Hospital Los Angeles show in vitro that expression of a protein known as MYCN, which has been associated with many different types of cancer, by neuroblastoma cells decreases their secretion of a soluble factor (CCL2) that attracts NKT cells. Similarly, in mice, NKT cells were largely inhibited from invading neuroblastomas overexpressing MYCN. Furthermore, individuals with neuroblastomas that expressed high levels of MYCN and whose cancer had spread to the bone marrow had substantially fewer NTK cells in their bone marrow than individuals with neuroblastomas that expressed low levels of MYCN and whose cancer had spread to the bone marrow. The authors therefore suggest that enhancing NKT cell localization to the tumor should be considered when designing new cancer therapeutics.
TITLE: Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma
AUTHOR CONTACT: Leonid S. Metelitsa Childrens Hospital Los Angeles, Los Angeles, California, USA. Phone: (323) 671-1839; Fax: (323) 664-9455; E-mail: email@example.com.
Steve Rutledge Director of Communications Childrens Hospital Los Angeles, Los Angeles, California, USA. Phone: (323) 361-4121; E-mail: firstname.lastname@example.org
View the PDF of this article at: https://www.the-jci.org/article.php?id=30751
GENETICS: 1, 2, 3: third gene responsible for genetic disorder identified
Tumoral calcinosis is an inherited disorder that is characterized by the presence of lumps of calcium at inappropriate sites in the body, such as around the hip, elbow, shoulder, and knee joints. Previously, mutations in two genes (FGF23 and GALNT3) had been shown to cause this disease. Now, re
|Contact: Karen Honey|
Journal of Clinical Investigation